P53 loss alone (Takeda et al., 2019) or QKI-5 (a transcriptional target of P53) decline in expression (Mukohyama et al., 2019) confers the metastatic ability to intestinal tumors. This evidence concerns the gene TP53 and intestinal neoplasm.